Drivers and Trajectories of Resistance to New First-Line Drug Regimens for Tuberculosis
Shrestha S, Knight GM, Fofana M, Cohen T, White RG, Cobelens F, Dowdy DW. Drivers and Trajectories of Resistance to New First-Line Drug Regimens for Tuberculosis. Open Forum Infectious Diseases 2014, 1: ofu073. PMID: 25734143, PMCID: PMC4281792, DOI: 10.1093/ofid/ofu073.Peer-Reviewed Original ResearchDrug-resistant TBTreatment of tuberculosisNew drug regimenTransmission fitnessDrug regimensDrug regimenTreatment successDrug-susceptible TBAppropriate second-line therapyDR-TB prevalenceSecond-line therapyDrug resistance trendsTreatment success rateHigher treatment successNovel drug regimensEmergence of resistancePopulation-level dataTB regimensShort-term surveillanceDS-TBNew regimenClinical trialsEarly diagnosisRegimensDrug resistancePopulation-Level Impact of Shorter-Course Regimens for Tuberculosis: A Model-Based Analysis
Fofana MO, Knight GM, Gomez GB, White RG, Dowdy DW. Population-Level Impact of Shorter-Course Regimens for Tuberculosis: A Model-Based Analysis. PLOS ONE 2014, 9: e96389. PMID: 24816692, PMCID: PMC4015982, DOI: 10.1371/journal.pone.0096389.Peer-Reviewed Original ResearchConceptsShort-course regimensTB incidenceTreatment completionTreatment successFirst-line treatment regimensFour-month regimenFour-month regimensLower treatment completionProportion of patientsPopulation-level incidenceSix-month therapyGlobal tuberculosis incidenceDynamic transmission modelPopulation-level transmissionCourse regimensTB diseaseTB patientsNew regimensRelapse rateTB mortalityTB transmissionTreatment regimensTuberculosis incidenceClinical trialsRegimens